Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® EP's PathBuilder™ Steerable Introducer Wins Approval from National Medical Products Administration of China (NMPA)

[2019-04-15] 

Shanghai, China – On March 8, 2019, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") obtained a registration certificate from National Medical Products Administration of China (NMPA) for the independently developed PathBuilder™ Steerable Introducer.
 
The PathBuilder™ Steerable Introducer is comprised of an introducer, a dilator and a guide wire. It is a specialized device for use in the radiofrequency ablation procedure on the patients suffering cardiac arrhythmia. With a vascular access through the femoral vein, the PathBuilder™ Steerable Introducer introduces an ablation catheter or a mapping catheter to each cardiac chamber, including the left atrium using the atrial transseptal puncture procedure.
 
Previously, the PathBuilder™ Transseptal Introducer independently developed by MicroPort® EP had already been approved by NMPA to launch in China. The NMPA approval for PathBuilder™ Steerable Introducer is set to help MicroPort® EP provide the doctors and patients with better introducer options in the field of complex cardiac arrhythmia. In addition, the integrated electrophysiological solutions of MicroPort® EP, which combine active devices with passive devices and devices with equipment, will be further improved to benefit more Chinese cardiac arrhythmia patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Receives CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System
[Next]:MicroPort® Announces Annual Results for 2018